AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|

26.9 C

New York

Tuesday, September 1, 2026

Paramount Skydance Corporation Announces Extension of Expiration Dates of Previously Announced Exchange Offers and Tender Offers

Cadbury brand Dairy Milk Oreo Candy (bar) recalled due to undeclared pistachio

Entain Transitions Sports Interaction and PartyCasino to Alberta’s Regulated iGaming Market

Tag: adults

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C.,...

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsAdults